Nurix Therapeutics Inc
NASDAQ:NRIX

Watchlist Manager
Nurix Therapeutics Inc Logo
Nurix Therapeutics Inc
NASDAQ:NRIX
Watchlist
Price: 19.83 USD -1.05% Market Closed
Market Cap: 1.4B USD
Have any thoughts about
Nurix Therapeutics Inc?
Write Note

Wall Street
Price Targets

NRIX Price Targets Summary
Nurix Therapeutics Inc

Wall Street analysts forecast NRIX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for NRIX is 32.75 USD with a low forecast of 16.16 USD and a high forecast of 43.05 USD.

Lowest
Price Target
16.16 USD
19% Downside
Average
Price Target
32.75 USD
65% Upside
Highest
Price Target
43.05 USD
117% Upside

NRIX Last Price Targets
Nurix Therapeutics Inc

The latest public price target was made on Oct 24, 2024 by David Dai from UBS , who expects NRIX stock to rise by 77% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
David Dai
UBS
35 USD
Upside 77%
1 month ago
Oct 24, 2024
UBS Starts Nurix (NRIX) at Buy
StreetInsider
Robert Burns
H.C. Wainwright
30 USD
Upside 51%
2 months ago
Oct 21, 2024
Nurix (NRIX) PT Raised to $30 at H.C. Wainwright
StreetInsider
Matthew Biegler
Oppenheimer
35 USD
Upside 77%
2 months ago
Oct 15, 2024
Nurix Therapeutics price target raised to $35 from $30 at Oppenheimer
TheFly
Derek Archila
Wells Fargo
32 USD
Upside 61%
2 months ago
Oct 15, 2024
Wells Fargo Reiterates Overweight Rating on Nurix (NRIX)
StreetInsider
Stephen Willey
Stifel Nicolaus
34 USD
Upside 71%
2 months ago
Oct 14, 2024
Nurix (NRIX) PT Raised to $34 at Stifel
StreetInsider
Roger Song
Jefferies
41 USD
Upside 107%
2 months ago
Oct 11, 2024
This Amazon Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Benzinga
Brian Skorney
Robert W. Baird
26 USD
Upside 31%
3 months ago
Sep 5, 2024
Nurix Therapeutics transferred with an Outperform at Baird
TheFly
Matthew Biegler
Oppenheimer
27 USD
Upside 36%
4 months ago
Aug 14, 2024
Nurix (NRIX) PT Raised to $27 at Oppenheimer
StreetInsider
Gregory Renza
RBC Capital
26 USD
Upside 31%
5 months ago
Jun 27, 2024
Nurix (NRIX) PT Raised to $26 at RBC Capital
StreetInsider
Robert Burns
H.C. Wainwright
26 USD
Upside 31%
6 months ago
Jun 18, 2024
Nurix (NRIX) PT Raised to $26 at H.C. Wainwright
StreetInsider
Tyler Van Buren
Piper Sandler
35 USD
Upside 77%
6 months ago
Jun 5, 2024
Piper Sandler Reiterates Overweight Rating on Nurix (NRIX)
StreetInsider
Gregory Renza
RBC Capital
23 USD
Upside 16%
8 months ago
Apr 11, 2024
Nurix (NRIX) PT Raised to $23 at RBC Capital
StreetInsider
Joel Beatty
Robert W. Baird
25 USD
Upside 26%
8 months ago
Apr 11, 2024
Nurix (NRIX) PT Raised to $25 at Baird
StreetInsider
Show More Price Targets
Show Less Price Targets
David Dai
UBS
Price Target 35 USD
Upside/Downside 77%
View Source
Robert Burns
H.C. Wainwright
Price Target 30 USD
Upside/Downside 51%
View Source
Matthew Biegler
Oppenheimer
Price Target 35 USD
Upside/Downside 77%
View Source
Derek Archila
Wells Fargo
Price Target 32 USD
Upside/Downside 61%
View Source
Stephen Willey
Stifel Nicolaus
Price Target 34 USD
Upside/Downside 71%
View Source
Roger Song
Jefferies
Price Target 41 USD
Upside/Downside 107%
View Source
Brian Skorney
Robert W. Baird
Price Target 26 USD
Upside/Downside 31%
View Source
Matthew Biegler
Oppenheimer
Price Target 27 USD
Upside/Downside 36%
View Source
Gregory Renza
RBC Capital
Price Target 26 USD
Upside/Downside 31%
View Source
Robert Burns
H.C. Wainwright
Price Target 26 USD
Upside/Downside 31%
View Source
Tyler Van Buren
Piper Sandler
Price Target 35 USD
Upside/Downside 77%
View Source
Gregory Renza
RBC Capital
Price Target 23 USD
Upside/Downside 16%
View Source
Joel Beatty
Robert W. Baird
Price Target 25 USD
Upside/Downside 26%
View Source
Show More Price Targets
Show Less Price Targets
Nurix Therapeutics Inc Competitors:
Price Targets
068270
Celltrion Inc
30% Upside
377740
BioNote Inc
20% Upside
ACAD
ACADIA Pharmaceuticals Inc
52% Upside
MRKR
Marker Therapeutics Inc
323% Upside
IOVA
Iovance Biotherapeutics Inc
229% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
36% Upside
BONEX
Bonesupport Holding AB
2% Downside
TGTX
TG Therapeutics Inc
29% Upside

Revenue
Forecast

Revenue Estimate
Nurix Therapeutics Inc

For the last 4 years the compound annual growth rate for Nurix Therapeutics Inc's revenue is 25%. The projected CAGR for the next 4 years is 5%.

25%
Past Growth
5%
Estimated Growth
Estimates Accuracy
-13%
Average Miss

Operating Income
Forecast

Operating Income Estimate
Nurix Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
3%
Average Beat

Net Income
Forecast

Net Income Estimate
Nurix Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-34%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is NRIX's stock price target?
Price Target
32.75 USD

According to Wall Street analysts, the average 1-year price target for NRIX is 32.75 USD with a low forecast of 16.16 USD and a high forecast of 43.05 USD.

What is Nurix Therapeutics Inc's Revenue forecast?
Projected CAGR
5%

For the last 4 years the compound annual growth rate for Nurix Therapeutics Inc's revenue is 25%. The projected CAGR for the next 4 years is 5%.

Back to Top